Xiaoou Sun

Dr. Xiaoou Sun


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
XSXingjuan Shi
Xingjuan Shi
XSXiaoou Sun
Xiaoou Sun

23 January 2019 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
YLYao Luo
Yao Luo
RZRanran Zeng
Ranran Zeng
QGQingqing Guo
Qingqing Guo
JXJianrong Xu
Jianrong Xu
XSXiaoou Sun
Xiaoou Sun
LWLing Wang
Ling Wang
We report the identification of 14 novel anticancer agents through established computational anticancer cell-based models. Among these novel hits, the compound G03 exhibits stronger inhibitory effects on the proliferation of MCF-7, HepG2, MDA-MB-231, HCTT116, and HeLa as compared with the FDA-approved sorafenib, with IC50 values of 4.61, 3.20, 2.82, 2.98, and 2.90 μM, respectively. The tubulin protein was validated to be a target of G03 using SPR, tubulin polymerization, immunofluorescence, and western blot assays. G03 is a novel structurally simple anticancer agent with unusual microtubule-stabilizing effects. Our study demonstrated the identification of bioactive small molecules by computational phenotypic modeling, which represents a feasible route toward innovative leads for chemical biology and medicinal chemistry.

1 October 2017 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
PDF file
HSHao Su
Hao Su
MPMarco Pistolozzi
Marco Pistolozzi
XSXingjuan Shi
Xingjuan Shi
XSXiaoou Sun
Xiaoou Sun
WTWen Tan
Wen Tan
The development of cardiac hypertrophy is a complicated process, which undergoes a transition from compensatory hypertrophy to heart failure, and the identification of new biomarkers and targets for this disease is greatly needed. Here we investigated the development of isoproterenol (ISO)-induced cardiac hypertrophy in an in vitro experimental model. After the induction of hypertrophy with ISO treatment in H9c2 cells, cell surface area, cell viability, cellular reactive oxygen species (ROS), and nitric oxide (NO) levels were tested. Our data showed that the cell viability, mitochondrial membrane potential, and NO/ROS balance varied during the development of cardiac hypertrophy in H9c2 cells. It was also found that the expression of thioredoxin1 (Trx1) and peroxiredoxin2 (Prdx2) was decreased during the cardiac hypertrophy of H9c2 cells. These results suggest a critical role for Trx1 and Prdx2 in the cardiac hypertrophy of H9c2 cells and in the transition from compensated hypertrophy to de-compensated hypertrophy in H9c2 cells, and our findings may have important implications for the management of this disease.

Verified
Journal Article
Open access
PDF file
XSXingjuan Shi
Xingjuan Shi
YWYujue Wang
Yujue Wang
XSXiaoou Sun
Xiaoou Sun
CWChan Wang
Chan Wang
PJPeng Jiang
Peng Jiang
MLMin Liu
Min Liu
Centrosome aberrations have been implicated in the development and progression of breast cancer. Our previous worked show that centrosomal protein 70 (Cep70) regulates breast cancer growth and metastasis. However, it remains elusive whether Cep70 is implicated in the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. Here we provide evidence that Cep70 is a mediator of paclitaxel sensitivity in breast cancer. Cell proliferation assays show that Cep70 expression correlates with paclitaxel sensitivity in breast cancer cell lines. In addition, paclitaxel sensitivity varies when altering Cep70 expression level. Mechanistic studies reveal that Cep70 interacts with tubulin, and promotes the ability of paclitaxel to stimulate microtubule assembly. These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer.